Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 14:17 PDT] Ventyx Biosciences, Inc. (NASDAQ:VTYX), Up By 100% ($1.11) From $1.11 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/28/2025 08:00 PDT] VTYX Expected to Trade Up After Bullish Patterns Develop
• [04/23/2025 10:29 PDT] Ventyx Biosciences, Inc. (NASDAQ:VTYX), Up By 100% ($1) From $1 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/16/2025 07:17 PDT] VTYX Expected to Trade Up After Bullish Patterns Develop
• [04/10/2025 07:37 PDT] VTYX Expected to Trade Up After Bullish Patterns Develop
• [03/04/2025 10:29 PST] Ventyx Biosciences, Inc. (NASDAQ:VTYX), Down By 100% ($1.62) From $1.62 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/03/2025 07:42 PST] VTYX Expected to Trade Up After Bullish Patterns Develop
• [02/28/2025 10:29 PST] Ventyx Biosciences, Inc. (NASDAQ:VTYX), Down By 100% ($1.67) From $1.67 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions